company background image
ETON logo

Eton Pharmaceuticals NasdaqGM:ETON Stock Report

Last Price

US$10.43

Market Cap

US$271.3m

7D

-1.6%

1Y

186.5%

Updated

20 Nov, 2024

Data

Company Financials +

Eton Pharmaceuticals, Inc.

NasdaqGM:ETON Stock Report

Market Cap: US$271.3m

ETON Stock Overview

A specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. More details

ETON fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for ETON from our risk checks.

Eton Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eton Pharmaceuticals
Historical stock prices
Current Share PriceUS$10.43
52 Week HighUS$11.11
52 Week LowUS$3.03
Beta1.26
11 Month Change23.58%
3 Month Change145.41%
1 Year Change186.54%
33 Year Change141.44%
5 Year Change65.03%
Change since IPO66.88%

Recent News & Updates

Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%

Nov 14
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%

Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?

Oct 07
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?

After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Recent updates

Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%

Nov 14
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%

Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?

Oct 07
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?

After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Dec 22
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous

Sep 13

Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story

Aug 14

Eton Pharma jumps 20% on FDA approval of seizure therapy

Jul 18

Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Apr 15
Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Oct 14
Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Another Look At Eton Pharmaceuticals

Sep 03

What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Aug 18
What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Eton Pharma wins FDA approval for Rezipres

Jun 15

FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment

May 28

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

May 15
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Apr 05
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Mar 01
Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Eton Pharma buys Canadian rights for Alkindi Sprinkle

Jan 14

Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

Jan 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

Shareholder Returns

ETONUS PharmaceuticalsUS Market
7D-1.6%-3.8%-1.0%
1Y186.5%9.8%30.3%

Return vs Industry: ETON exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.

Return vs Market: ETON exceeded the US Market which returned 30.4% over the past year.

Price Volatility

Is ETON's price volatile compared to industry and market?
ETON volatility
ETON Average Weekly Movement8.9%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: ETON has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ETON's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201730Sean Brynjelsenwww.etonpharma.com

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis.

Eton Pharmaceuticals, Inc. Fundamentals Summary

How do Eton Pharmaceuticals's earnings and revenue compare to its market cap?
ETON fundamental statistics
Market capUS$271.28m
Earnings (TTM)-US$5.48m
Revenue (TTM)US$34.68m

7.8x

P/S Ratio

-49.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ETON income statement (TTM)
RevenueUS$34.68m
Cost of RevenueUS$14.11m
Gross ProfitUS$20.57m
Other ExpensesUS$26.05m
Earnings-US$5.48m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.21
Gross Margin59.30%
Net Profit Margin-15.81%
Debt/Equity Ratio25.8%

How did ETON perform over the long term?

See historical performance and comparison